Market research
NANO.PA Nanobiotix S.A
PA EUR Healthcare
Latest close
As of 30 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 974M
- P/E ratio
- Not available
- Analyst target
- 52.2
- Dividend yield
- Not available
- Beta
- 0.59
Profile
Instrument facts
- Exchange
- PA
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- FR0011341205
- Market cap
- 974M
- P/E ratio
- Not available
- Analyst target
- 52.2
- Dividend yield
- Not available
- Beta
- 0.59
About
About Nanobiotix S.A
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck, liver, prostate, pancreatic, esophageal, rectal, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is based in Paris, France.
Research context
Nanobiotix S.A appears in PyInvesting’s Paris Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the NANO.PA discussion.
5 years, 6 months ago
Nanobiotix S.A is currently in a long term downtrend where the price is trading 2.2% below its 200 day moving average.
From a valuation standpoint, the stock is 1518.0% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 4423.3.
Nanobiotix S.A's total revenue sank by 89.7% to $37K since the same quarter in the previous year.
Its net income has dropped by 52.5% to $-21M since the same quarter in the previous year.
Finally, its free cash flow grew by 35.1% to $-6M since the same quarter in the previous year.
Based on the above factors, Nanobiotix S.A gets an overall score of 1/5.